-
1
-
-
0035880957
-
Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
-
Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3622-3634
-
-
Balch, C.M.1
Soong, S.J.2
Gershenwald, J.E.3
-
2
-
-
0030030347
-
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
-
Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
-
(1996)
J Clin Oncol
, vol.14
, pp. 7-17
-
-
Kirkwood, J.M.1
Strawderman, M.H.2
Ernstoff, M.S.3
-
3
-
-
1842520646
-
Interferons and adjuvant therapy
-
Balch C, Houghton AN, Sober A, Soong S-J, eds., St. Louis, MO: Quality Medical Publishing, Inc.
-
Agarwala S, Kirkwood JM. Interferons and adjuvant therapy. In: Balch C, Houghton AN, Sober A, Soong S-J, eds. Cutaneous Melanoma. St. Louis, MO: Quality Medical Publishing, Inc., 2003:605-621.
-
(2003)
Cutaneous Melanoma
, pp. 605-621
-
-
Agarwala, S.1
Kirkwood, J.M.2
-
5
-
-
84873597250
-
-
Oncology Drugs Advisory Committee meeting, Washington DC, February 27, http://www.fda.gov/ohrms/dockets/ac/02 /slides/3838s1.htm. Accessed: Sept 16, 2003
-
Kirkwood JM. Issues in the clinical development of investigational agents being evaluated for the post-surgical adjuvant treatment of high-risk (stages IIb and III) melanoma. In: Federal Drug Administration, Oncology Drugs Advisory Committee meeting, Washington DC, February 27, 2002. Available at: http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3838t1.htm, http://www.fda.gov/ohrms/dockets/ac/02 /slides/3838s1.htm. Accessed: Sept 16, 2003.
-
(2002)
Issues in the Clinical Development of Investigational Agents Being Evaluated for the Post-surgical Adjuvant Treatment of High-risk (Stages IIb and III) Melanoma
-
-
Kirkwood, J.M.1
-
6
-
-
0036534376
-
Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials
-
Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818-1825.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1818-1825
-
-
Lens, M.B.1
Dawes, M.2
-
7
-
-
0034088027
-
High-and lowdose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
-
Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and lowdose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2444-2458
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sondak, V.K.3
-
8
-
-
0001574743
-
Interferon-α as adjuvant therapy for melanoma: A Meta-analysis of the randomised trials
-
San Francisco, CA, May 15
-
Wheatley K, Hancock B, Gore M, et al. Interferon-α as adjuvant therapy for melanoma: a Meta-analysis of the randomised trials. Proceedings of ASCO, San Francisco, CA, May 15, 2001, Vol. 20.
-
(2001)
Proceedings of ASCO
, vol.20
-
-
Wheatley, K.1
Hancock, B.2
Gore, M.3
-
9
-
-
84873597250
-
-
Oncology Drugs Advisory Committee meeting, Washington DC, February 27, 2002. http://www.fda.gov/ohrms/dockets/ac/02/slides/3838s1.htm. Accessed: Sept 16, 2003
-
Cardinali M, Tiwari J. Issues in the clinical development of investigational agents being evaluated for the post-surgical adjuvant treatment of high-risk (stages IIb and III) melanoma., Federal Drug Administration, Oncology Drugs Advisory Committee meeting, Washington DC, February 27, 2002, 2002. Available at: http://www.fda.gov/ohrms/dockets/ac/02/ transcripts/3838t1. htm, http://www.fda.gov/ohrms/dockets/ac/02/slides/3838s1.htm. Accessed: Sept 16, 2003.
-
(2002)
Issues in the Clinical Development of Investigational Agents Being Evaluated for the Post-surgical Adjuvant Treatment of High-risk (Stages IIb and III) Melanoma
-
-
Cardinali, M.1
Tiwari, J.2
-
10
-
-
7144264391
-
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
-
Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16:1425-1429.
-
(1998)
J Clin Oncol
, vol.16
, pp. 1425-1429
-
-
Pehamberger, H.1
Soyer, H.P.2
Steiner, A.3
-
11
-
-
7144228601
-
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
-
Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-1910.
-
(1998)
Lancet
, vol.351
, pp. 1905-1910
-
-
Grob, J.J.1
Dreno, B.2
De La Salmoniere, P.3
-
12
-
-
0035883950
-
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial
-
Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358:866-869.
-
(2001)
Lancet
, vol.358
, pp. 866-869
-
-
Cascinelli, N.1
Belli, F.2
MacKie, R.M.3
-
13
-
-
0035805053
-
Adjuvant interferon alpha 2b in high risk melanoma - The Scottish study
-
Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001;84:1146-1149.
-
(2001)
Br J Cancer
, vol.84
, pp. 1146-1149
-
-
Cameron, D.A.1
Cornbleet, M.C.2
MacKie, R.M.3
-
14
-
-
0035339880
-
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: Results of intergroup trial E1694/S9512/C509801
-
Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2370-2380
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sosman, J.A.3
-
15
-
-
0035967235
-
Paroxetine for the prevention of depression induced by high-dose interferon alfa
-
Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966.
-
(2001)
N Engl J Med
, vol.344
, pp. 961-966
-
-
Musselman, D.L.1
Lawson, D.H.2
Gumnick, J.F.3
|